Salomao R, Rigato O, Pignatari A, Freudenberg M, Galanos C
Infection. 1999; 27(1):1-11.
PMID: 10027099
DOI: 10.1007/BF02565163.
Bailat S, Heumann D, Le Roy D, Baumgartner J, Rietschel E, Glauser M
Infect Immun. 1997; 65(2):811-4.
PMID: 9009348
PMC: 176131.
DOI: 10.1128/iai.65.2.811-814.1997.
Warren H, Amato S, Fitting C, Black K, Loiselle P, Pasternack M
J Exp Med. 1993; 177(1):89-97.
PMID: 8418211
PMC: 2190862.
DOI: 10.1084/jem.177.1.89.
Di Padova F, Brade H, Barclay G, Poxton I, Liehl E, SCHUETZE E
Infect Immun. 1993; 61(9):3863-72.
PMID: 8359907
PMC: 281087.
DOI: 10.1128/iai.61.9.3863-3872.1993.
de Kievit T, Lam J
J Bacteriol. 1994; 176(23):7129-39.
PMID: 7525538
PMC: 197099.
DOI: 10.1128/jb.176.23.7129-7139.1994.
A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Results in healthy subjects and in patients infected by gram-negative bacteria.
Nys M, Damas P, Damas F, Joassin L, Demonty J
Med Microbiol Immunol. 1987; 176(5):257-71.
PMID: 3657701
DOI: 10.1007/BF00190532.
Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.
Bogard Jr W, Dunn D, Abernethy K, Kilgarriff C, Kung P
Infect Immun. 1987; 55(4):899-908.
PMID: 3549565
PMC: 260436.
DOI: 10.1128/iai.55.4.899-908.1987.
Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.
Fenwick B, Cullor J, Osburn B, OLANDER H
Infect Immun. 1986; 53(2):298-304.
PMID: 3525407
PMC: 260874.
DOI: 10.1128/iai.53.2.298-304.1986.
Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.
Vreede R, Leuvenink J, Bouter A, Brouwer E, Marcelis J, Verhoef J
Eur J Clin Microbiol. 1986; 5(2):141-7.
PMID: 3522225
DOI: 10.1007/BF02013969.
Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.
Dunn D
World J Surg. 1987; 11(2):233-40.
PMID: 3296482
DOI: 10.1007/BF01656407.
Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5.
Overbeek B, Schellekens J, Lippe W, Dekker B, Verhoef J
J Clin Microbiol. 1987; 25(6):1009-13.
PMID: 2439534
PMC: 269125.
DOI: 10.1128/jcm.25.6.1009-1013.1987.
Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides.
Pollack M, Raubitschek A, Larrick J
J Clin Invest. 1987; 79(5):1421-30.
PMID: 2437155
PMC: 424413.
DOI: 10.1172/JCI112970.
Use of synthetic antigens to determine the epitope specificities of monoclonal antibodies against the 3-deoxy-D-manno-octulosonate region of bacterial lipopolysaccharide.
Brade L, Kosma P, Appelmelk B, Paulsen H, Brade H
Infect Immun. 1987; 55(2):462-6.
PMID: 2433221
PMC: 260351.
DOI: 10.1128/iai.55.2.462-466.1987.
A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide.
Tsang R, Chan K, Chau P, Wan K, Ng M, Schlecht S
Infect Immun. 1987; 55(1):211-6.
PMID: 2432013
PMC: 260304.
DOI: 10.1128/iai.55.1.211-216.1987.
Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.
Bouter A, Marcelis J, Schellekens J, Verhoef J
Eur J Clin Microbiol. 1986; 5(2):148-51.
PMID: 2424754
DOI: 10.1007/BF02013970.
Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.
Schellekens J, Verhoef J
Infect Immun. 1990; 58(2):421-6.
PMID: 2404871
PMC: 258473.
DOI: 10.1128/iai.58.2.421-426.1990.
Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.
Mitov I, Terziiski D
Infection. 1991; 19(6):383-90.
PMID: 1816107
DOI: 10.1007/BF01726444.